2nd Annual Obesity & Cardiometabolic Innovation Forum

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines, helping make people’s lives easier, fuller and longer.

Eos SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging. Eos’s lead clinical candidates, PTC-2105 and PTC-2107, both proprietary MitoXcel™ geropeptides, have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the “Δψm”. These two mechanisms include (1) the return of the efficiency of mitochondrial function in aging cells almost immediately back to their younger, more efficient phenotype, and (2) the profound elimination of senescent cells throughout every organ in the body, including the brain, reducing their negative systemic inflammatory effects. Extensive preclinical studies suggest the MitoXcel™ platform may be a broad gerotherapeutic that improves body composition, increasing lean muscle mass, and enhancing physical function in aging animals. By targeting fundamental processes driving aging and aging-related diseases, Eos SENOLYTIX is pursuing a unique therapeutic opportunity to intervene in the aging process in ways that were once thought impossible. Eos SENOLYTIX is headquartered in Houston, Texas and operates within the broader SENOTHERAPEUTIX/GEROTHERAPEUTIX group of longevity companies, which focuses on developing therapeutics targeting fundamental drivers of aging to improve healthspan and lifespan. For more information, visit https://www.eossenolytix.com

Alphala Co., Ltd. is a clinical-stage biotechnology company advancing ALP001E, a novel oral small molecule designed to directly target insulin resistance, the underlying driver of type 2 diabetes and cardiometabolic diseases. In early human studies, ALP001E demonstrated rapid and substantial improvements in insulin resistance and glycemic control, with a profile distinct from existing therapies. By addressing the root cause rather than downstream symptoms, Alphala aims to redefine the treatment paradigm beyond GLP-1–based approaches and unlock new opportunities across the broader metabolic disease spectrum.

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.

MitoRx Therapeutics (UK) is developing a first-in-class small-molecule weight loss therapy addressing the key unmet need in a GLP-1 dominated obesity market: targeted fat loss with preservation of lean mass and preservation of muscle function, a TPP that is clearly differentiated from standard-of-care GLP-1 drugs.

Nitinotes is a privately held medical device company pioneering an innovative solution for the treatment of obesity. The Company's flagship product, EndoZip™, is a fully automated endoscopic sleeve gastroplasty (ESG) system designed to provide a consistent, reproducible, and minimally invasive alternative to traditional bariatric surgery for patients with class I & II obesity.

Perspectum is a global leader in quantitative metabolic imaging, focused on enabling differentiation in the rapidly intensifying obesity and cardiometabolic market. In the GLP-1 era – where weight loss alone is no longer sufficient – sponsors must demonstrate deeper, organ-level impact to compete. Perspectum provides validated imaging biomarkers and integrated trial expertise that generate that evidence. In obesity and related metabolic disease, Perspectum quantifies changes in body composition, muscle, liver, heart, kidney, and pancreas – including adiposity distribution, muscle quality, liver fat, inflammation, fibrosis, and broader cardiometabolic involvement. These data-rich endpoints enable sponsors to demonstrate mechanistic impact, evaluate combination effects, stratify patient populations, and build meaningful differentiation beyond headline efficacy metrics. The company brings extensive experience supporting late-phase metabolic programs, including MASH, alongside proprietary expertise in quantitative inflammation assessment and global multi-center standardization of imaging biomarkers. Through its Pharma Solutions group, Perspectum partners with biopharma sponsors across more than 90 commercial clinical trials in metabolic and inflammatory disease. By integrating proprietary biomarker development with global operational delivery and regulatory expertise, Perspectum helps sponsors strengthen competitive positioning and accelerate evidence generation in obesity drug development.

PriveBio is a precision medicine biotech focused on discovering and developing novel medicines to cure fibro-inflammation in cardiometabolic, renal diseases and obesity that address unmet medical need in the post-GLP1 era. Powered by proprietary high dimensionality patient-derived genetics, multi-omics, and an adipocyte / fibroblast - centric discovery platform, the company is advancing a portfolio of first-in-class therapeutics and blood-based detection assays to deliver impact for patients as efficiently as possible validated by human genetics. PRV-101 our lead asset, addressing > $15B TAM, is in IND-enabling studies with line of sight to the clinic in 2027.

Rivus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health. The company’s lead candidate, HU6, is a potential best-in-class oral therapeutic to treat MASH currently advancing in the Phase 2 AMPLIFY trial. Rivus is also advancing RV-8451, the industry’s first muscle-preserving, oral GLP-1, in preclinical development to treat obesity. Rivus’ proprietary platform is focused on developing oral medicines that incorporate energy expenditure to deliver improved and sustained cardiometabolic health. Follow Rivus on  LinkedIn  and  X  and visit  the company website for more information.